

[Mesna](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.5. Supportive medicines](#)

ATC codes: [V03AF01](#)

EMLc

Indication

Rhabdomyosarcoma primary site ICD11 code: [2C25.Z](#)

INN

Mesna

Medicine type

Chemical agent

List type

Complementary

Additional notes

*injection solution may also be used for oral administration.

Formulations

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule ; 100 mg per mL in 10 mL ampoule ; 100 mg per mL in 2 mL ampoule

Oral > Solid > tablet: 400 mg ; 600 mg

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer Cancer supportive care

Wikipedia

[Mesna](#)

DrugBank

[Mesna \(Coenzyme M\)](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a 2 mL vial size of mesna solution for injection to the EML and EMLc. - the addition of a footnote indicating that the injection solution may also be used for oral administration.